> FVIIa or FVIII with e micizumab based on preclinical experiments. Emicizumab increases coagulation potential, therefore the FVIIa or FVIII dose required to achieve haemostasis may be lower than when used without HEMLIBRA prophylaxis. 
> FVIIa in patients receiving HEMLIBRA prophylaxis is limited. However, the possibility of thrombotic events should be considered when systemic anti -fibrinolyti cs are used in combination with a
